Physician profile
Mark Chu
NPI 1588755565
$10,660.14
in general payments reported to CMS, 2019-2025
34 companies · $2,202 in 2025
The $2,202 reported for 2025 was more than what 81% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,550 · 2020: $783 · 2021: $1,672 · 2022: $1,393 · 2023: $1,387 · 2024: $1,672 · 2025: $2,202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,261.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $3,866.60 | 2019-2025 | |
| Abbvie INC. | $1,523.84 | 2020-2025 | Viberzi, Linzess, Skyrizi |
| Pfizer INC. | $1,190.30 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $959.42 | 2019-2025 | Xifaxan, Trulance |
| Madrigal Pharmaceuticals | $619.77 | 2024-2025 | Rezdiffra |
| Phathom Pharmaceuticals, INC. | $408.56 | 2024-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $228.94 | 2024-2025 | Zenpep |
| Fujifilm Healthcare Americas Corporation | $223.39 | 2021-2023 | Fujifilm |
| Qol Medical, LLC | $175.00 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $147.34 | 2022-2023 | Zeposia |
| Ardelyx, INC. | $136.33 | 2024-2025 | Ibsrela |
| Sirtex Medical INC | $134.49 | 2023 | Sir-Spheres Microspheres |
| Romark Laboratories, Lc | $129.11 | 2019 | |
| Angiodynamics, INC. | $125.00 | 2024 | Nanoknife |
| Medtronic, INC. | $110.96 | 2025 | Interstim |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $80.66 | 2023 | Evis Exera Lll Colonovideoscope |
| Redhill Biopharma INC. | $70.29 | 2021-2022 | |
| Janssen Biotech, INC. | $68.94 | 2022-2025 | Tremfya |
| Horizon Therapeutics Plc | $48.60 | 2023 | Krystexxa |
| Hologic Sales and Service, LLC | $46.89 | 2019-2021 | |
| Celgene Corporation | $40.89 | 2023 | Zeposia |
| Intra-Sana Laboratories | $37.70 | 2022-2023 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Concordia Pharmaceuticals INC. | $37.39 | 2019 | |
| Allergan, INC. | $36.38 | 2019 | |
| Celltrion USA INC. | $30.03 | 2025 | Vegzelma |
| Intuity Medical INC | $23.40 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Global Blood Therapeutics, INC. | $23.14 | 2021 | |
| Shire North American Group INC | $22.56 | 2019 | |
| Lilly USA, LLC | $21.42 | 2024 | Zepbound, Jardiance |
| Regeneron Healthcare Solutions, INC. | $21.26 | 2025 | Dupixent |
| Nestle Healthcare Nutrition INC. | $20.44 | 2021 | |
| Vivus LLC | $19.15 | 2025 | Pancreaze |
| Ironwood Pharmaceuticals, INC | $19.03 | 2023 | Linzess |
| Micro-Tech Endoscopy USA, INC. | $12.92 | 2024 | Sureclip |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Chu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.